Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02987777

Enrollment

Registered

2016-12-09

Start date

2016-01-31

Completion date

2016-08-31

Last updated

2016-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer

Brief summary

The aim of this study was to assess the frequency of PD-L1 expression in stage III-IV ECs and to investigate its correlation impact with progression-free survival (PFS), and clinicopathological features including microsatellite instability and quantified stromal and intraepithelial tumor-infiltrating CD8+ lymphocytes (TILs)

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients consecutively enrolled from January 2004 to December 2014 treated for Endometrial cancer * Stage III-IV endometrial cancer with available tissue blocks, including biopsies, hysterectomy specimens and resections of metastatic foci

Exclusion criteria

* A patient record captured outside the time frame from January 2004 to December 2014

Design outcomes

Primary

Measure	Time frame
progression-free survival	84 months

Outcome results